drug · Product Intelligence

Cariprazine
Pipeline Intelligence

Cariprazine: 3 indexed trials, 2 sponsors; 8 linked Orange Book patents and 7 FDA-linked events where matched.

⚗

3Indexed trials

▦

2Sponsors

⌁

8Orange Book patent links

◎

7FDA-linked events

NCT03738215AbbVie · depressionPHASE3

NCT03739203AbbVie · depressionPHASE3

NCT05913947Aalborg University Hospital · depressionPHASE4

7737142*PEDVRAYLAR · app 2043702030-03-17

RE47350*PEDVRAYLAR · app 2043702030-01-16

RE49110*PEDVRAYLAR · app 2043702030-01-16

7737142VRAYLAR · app 2043702029-09-17

RE47350VRAYLAR · app 2043702029-07-16

RE49110VRAYLAR · app 2043702029-07-16

7943621*PEDVRAYLAR · app 2043702029-06-20

7943621VRAYLAR · app 2043702028-12-20

FDA_EXCLUSIVITYVRAYLAR · PED2029-06-18

FDA_EXCLUSIVITYVRAYLAR · M-142028-12-18

FDA_EXCLUSIVITYVRAYLAR · NPP2028-12-18

FDA_APPROVALVRAYLAR · 2025-12-18

FDA_APPROVALCARIPRAZINE HYDROCHLORIDE · 2025-12-16

FDA_APPROVALCARIPRAZINE HYDROCHLORIDE · 2022-09-30

FDA_APPROVALCARIPRAZINE HYDROCHLORIDE · 2022-09-09

FDA Orange Book coverage is U.S.-specific and is not a substitute for worldwide patent or regulatory review.

CariprazinePipeline Intelligence